Tuesday, 17 Sep 2019

You are here

Pegloticase Infusion Reactions Largely Seen in Non-Responders

The introduction of intravenous pegloticase (PEG) in 2010 was felt by many to be a major advance in the treatment of patients with severe, refractory tophaceous gout.  But for some, concerns over infusion reactions and safety have limited its use.

Calabrese and colleagus have analyzed patient data from clinical trials to assess the frequency or severity of infusion reactions and compared rates of infusion reactions (IRs) in responders and nonresponders

IRs from two RCTs of pegloticase were evaluated and categorized as anaphylaxis, hypersensitivity, or other. Serum levels of tryptase and total hemolytic complement (CH50) were evaluated at the time of all IRs. Frequency of IRs by each category was evaluated in all subjects, responders or nonresponders to pegloticase.

In total there were 113 IRs amongh 1695 infusions; with a rate of 6.7%. Only 6/113 met criteria for anaphylaxis (overall anaphylaxis risk 0.35%), according to the National Institute of Allergy and Infectious Disease/Food and Allergy and Anaphylaxis Network (NIAID/FAAN) criteria.  Hypersensitivity was seen in 53, with only one feature of anaphylaxis criteria.

Infusion reactions were higher in nonresponders compared to responders, whether pegloticase was given every 2 weeks (9.8% nonresponders vs 0.5% in responders) or every 4 weeks IV (12.2% vs 2.6%).

There were no differences among in types of IRs with regard to clinical course or biochemical evidence of immune activation determined by CH50 or tryptase levels.

Thus, IRs were common in nonresponders. Anaphylaxis was not associated with immune activation or a more severe course. The authors stated that the safety prescribing rule to discontinue PEG if uric acid rises to >6 mg/dL, is important to avoid and decrease the frequency of IRs.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.